Caribou Biosciences, Inc. (CRBU) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19
	10-K	10-K	10-K	10-K
Revenues:
Rest of world	0.5	0.7
Non-US			0.4	0.4
UNITED STATES	13.3	8.9	12.0	5.3
Total revenues	13.9	9.6	12.4	5.8
Revenue growth [+]	44.3%	-22.4%	113.6%
Rest of world	-20.0%
Non-US			-18.5%
UNITED STATES	49.3%	-25.7%	124.4%
Cost of goods sold	0.0	0.0	0.0	0.0
Gross profit	13.9	9.6	12.4	5.8
Gross margin	100.0%	100.0%	100.0%	100.0%
Selling, general and administrative [+]	38.0	24.3	14.1	16.5
General and administrative	38.0	24.3	14.1	16.5
Research and development	82.2	52.3	34.4	23.6
EBITDA [+]	-104.8	-66.0	-35.2	-33.6
EBITDA growth	58.8%	87.4%	5.0%
EBITDA margin	-756.5%	-687.6%	-285.0%	-579.7%
Depreciation and amortization	1.6	1.0	0.9	0.8
EBIT [+]	-106.4	-67.0	-36.1	-34.3
EBIT growth	58.9%	85.4%	5.3%
EBIT margin	-768.2%	-697.8%	-292.2%	-592.7%
Interest income, net [+]			0.2	1.0
Interest expense			0.0	0.0
Interest income			0.2	1.0
Other income (expense), net [+]	7.0	0.4	-0.2	2.3
Gain (loss) on debt retirement		1.6
Other non-operating income	4.8	0.2	0.5
Other	4.8	0.2	-0.5
Pre-tax income	-99.4	-66.6	-36.1	-31.0
Income taxes	0.1	0.3	-1.8	-7.5
Tax rate			5.0%	24.3%
Net income	-99.4	-66.9	-34.3	-23.4
Net margin	-717.8%	-697.3%	-277.6%	-404.8%

Basic EPS [+]	($1.64)	($2.11)	($4.01)	($2.80)
Growth	-22.6%	-47.3%	43.5%
Diluted EPS [+]	($1.64)	($2.11)	($4.01)	($2.80)
Growth	-22.6%	-47.3%	43.5%

Shares outstanding (basic) [+]	60.8	31.7	8.5	8.4
Growth	92.0%	270.5%	2.1%
Shares outstanding (diluted) [+]	60.8	31.7	8.5	8.4
Growth	92.0%	270.5%	2.1%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.